

CURRENT ACHIEVEMENTS OF DENDRITIC CELL-BASED IMMUNOTHERAPY

Tanja Džopalić^{1,2}, Marija Topalović¹, Marko Bjelaković^{1,2}

¹University of Niš, Faculty of medicine, Niš, Serbia

²Clinical Center Niš, Pulmonary Diseases Clinic, Niš, Serbia

Contact: Tanja Džopalić

Blvd. Dr Zoran Djindjić 81, 18000 Nis, Serbia

E-mail: tanja.dzopalic@medfak.ni.ac.rs

tanjche80@gmail.com

Dendritic cells (DCs) are the key antigen-presenting cells and stimulators of the immune response. Numerous studies have proven DC-based tumor vaccines as the most effective form of tumor vaccines with good results in clinical trials. Due to the marked disproportion in the results of complete tumor curing in some patients using DC-based vaccines and modest results achieved in other patients, there is a need for improvement of preparation methods. This review summarizes the current protocols in creating DC-based tumor vaccines and future perspectives as well.

Acta Medica Medianae 2019;58(2):111-117.

Key words: *dendritic cells, immunotherapy, cancer vaccines*